May 19, 2016 19 00 AEST
This event has now ended:

olaparib in HGSOC

olaparib in HGSOC

This event is part of a medical education meeting series supported by AstraZeneca designed to provide an overview of best practice serous ovarian cancer (HGSOC).*

•  Hear from local clinical experts about:

  • how to use LynparzaTM in the clinical setting, 
  • manage adverse events, and define progression
  • their own experience with LynparzaTM illustrated with patient case studies.

• Review the clinical data supporting use of LynparzaTM as a maintenance therapy in BRCAm PSR disease.*

•  Consider the role of early BRCAm testing in ovarian cancer to inform treatment decisions.
•  Revisit your own experience in treating patients with high-grade serous ovarian cancer.


*LynparzaTM is indicated as monotherapy for the maintenance treatment of patients with platinum sensitive relapsed BRCA-mutated (germline or somatic) high grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) after platinum-based chemotherapy. Prior treatment must have included at least two courses of platinum-based regimens.1
More about the event:
For any information or questions please view our FAQ's and support page

FAQ & Support

Show FAQ